Ventyx Biosciences stock initiated with Buy rating at Clear Street

  Ventyx Biosciences Inc (NASDAQ:VTYX) received a Buy rating initiation from Clear Street on Tuesday, with a price target of $11.00. 

The research firm cited upcoming catalysts for NLRP3 inhibitors expected in the fourth quarter of 2025 that could drive valuation and partnership opportunities for the biopharmaceutical company.

Clear Street highlighted VTX2735, Ventyx’s peripheral drug, which may advance to pivotal trials for recurrent pericarditis following data expected in the fourth quarter of 2025. The firm noted this indication represents a potential $3 billion-plus U.S. total addressable market.

The analyst report also mentioned VTX3232, a CNS-penetrant NLRP3 inhibitor with fourth-quarter 2025 data readouts in obesity-related cardiometabolic diseases that will trigger Sanofi’s right-of-first-negotiation window.

https://www.investing.com/news/analyst-ratings/ventyx-biosciences-stock-initiated-with-buy-rating-at-clear-street-93CH-4264781